In February 2026, China’s National Healthcare Security Administration (NHSA) introduced the Measures for Pre-Communication on Reference Drugs (Interim) . While technical in nature, the policy represents an interesting initiative within China’s evolving pharmacoeconomic framework and may have practical implications for companies preparing for reimbursement discussions. At its core, the new mechanism allows pharmaceutical companies to communicate with the NHSA in advance to det

[Auckland, New Zealand] — MAAB Group today announced the signing of a strategic licensing agreement to bring Sancuso® (granisetron transdermal system) across Greater China. Under the agreement, MAAB will assume exclusive manufacturing and commercialisation rights for Sancuso® in the region. The company plans to establish local production capacity in China to improve accessibility for patients and ensure a stable, cost-efficient supply chain.   Sancuso ® Relaunch Marks First

In the ever-evolving world of healthcare, having reliable access to high-quality reference medicines is essential for research,...